Recently, various linear source models, for example, 103Pd RadioCoil, have been introduced to overcome the shortcomings of traditional "seed" type interstitial prostate brachytherapy implants, such as migration and clumping of the seeds. However, the existing prostate treatment-planning systems have not been updated to perform dose calculation for implants with linear sources greater than 1.0 c...

To address the limited availability of radiation shielding data for brachytherapy as well as some disparity in existing data, Monte Carlo simulation was used to generate radiation transmission data for 60Co, 137CS, 198Au, 192Ir 169Yb, 170Tm, 131Cs, 125I, and 103pd photons through concrete, stainless steel, lead, as well as lead glass and baryte concrete. Results accounting for the oblique incid...

With the increasing aged population, prostate cancer has become one of the commonest malignant tumors in the United States. The incidence of prostate cancer is the highest among malignant tumors in males, and the mortality rate is the second highest following lung cancer. Even when prostate cancer is diagnosed to be in the early stage preoperatively, its excised lesions are often judged pathohi...

Cyclotrons are particle accelerator machines which have many applications in industry, technology and medicine. Cyclotrons play an important role in medicine and about 50% of the all particle accelerators running in the world are used in medicine for radiation therapy, medical radioisotopes production, and biomedical research. In this short review the use of cyclotrons for a radiation therapy m...

PURPOSE Several isotopes are available for low dose-rate brachytherapy of the prostate. Currently, most implants use a single isotope. However, the use of dual-isotope implants may yield an advantageous combination of characteristics such as half-life and relative biological effectiveness. However, the use of dual-isotope implants complicates treatment planning and quality assurance. Do the ben...

OBJECTIVE Low dose rate (LDR) prostate brachytherapy (permanent 125I or 103Pd seeds) is an accepted treatment option for low risk prostate cancer patients. However, differences in prostate spatial location, volume and gland deformation between the images obtained during pre-planning and later on during the implant procedure prevent the pre-planned intended dose to be accurately delivered. We ar...